SLAM
CORT icon

Swiss Life Asset Management’s Corcept Therapeutics CORT Stock Holding History

Swiss Life Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$582K Buy
6,691
+711
+12% +$42.9K ﹤0.01% 888
2026
Q1 		$241K Buy
+5,980
New +$224K ﹤0.01% 1262
2025
Q4 		– Sell
-4,519
Closed -$376K – 1389
2025
Q3 		$376K Buy
+4,519
New +$327K ﹤0.01% 810

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss Life Asset Management's CORT Position: Q2 2026 in Review

Swiss Life Asset Management increased its Corcept Therapeutics (CORT) stake by 12% in Q2 2026, buying an estimated $42.9K and bringing the position to 6,691 shares worth $582K. The position accounts for ﹤0.01% of the portfolio, ranked #888.

Swiss Life Asset Management first reported a position in CORT in Q3 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Swiss Life Asset Management held 6,691 shares of Corcept Therapeutics worth $582K as of Q2 2026.
  • Swiss Life Asset Management bought 711 Corcept Therapeutics shares in Q2 2026, an estimated $42.9K.
  • Corcept Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #888 holding.
  • Swiss Life Asset Management first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.